LSTA
Lisata Therapeutics, Inc.
Biotechnology
Market Cap$29M
5Y Perf.-88.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LSTA vs CRVS
Revenue, margins, valuation, and 5-year total return — side by side.
CRVS
Corvus Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.23B
5Y Perf.+322.9%
LSTA vs CRVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LSTA | CRVS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $29M | $1.23B |
| Revenue (TTM) | $170K | $0.00 |
| Net Income (TTM) | $-17M | $-44M |
| Gross Margin | 91.2% | — |
| Operating Margin | -107.1% | — |
| Total Debt | $0.00 | $937K |
| Cash & Equiv. | $16M | $5M |
LSTA vs CRVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LSTA
CRVS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Lisata Therapeutics… (LSTA) | 100 | 11.3 | -88.7% |
| Corvus Pharmaceutic… (CRVS) | 100 | 422.9 | +322.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LSTA vs CRVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CRVS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Lisata Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
LSTA
Lisata Therapeutics, Inc.
The Income Pick
LSTA is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.17
- Lower volatility, beta 1.17, current ratio 5.76x
- Beta 1.17, current ratio 5.76x
Best for: income & stability and sleep-well-at-night
CRVS
Corvus Pharmaceuticals, Inc.
The Growth Play
CRVS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 48.0%
- 17.1% 10Y total return vs LSTA's -96.8%
- -6.6% revenue growth vs LSTA's -83.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CRVS | -6.6% revenue growth vs LSTA's -83.0% |
| Quality / Margins | CRVS | 3.5% margin vs LSTA's -97.6% |
| Stability / Safety | LSTA | Beta 1.17 vs CRVS's 1.63 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CRVS | +355.9% vs LSTA's +40.4% |
| Efficiency (ROA) | CRVS | -35.7% ROA vs LSTA's -70.8%, ROIC -78.1% vs -229.7% |
LSTA vs CRVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
LSTA vs CRVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLSTALAGGINGCRVS
CRVSCorvus Pharmaceutical…
2leads
LSTALisata Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs CRVSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LSTA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CRVS4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CRVS6/6
Risk & VolatilityBeta, volatility, and downside exposure
LSTA2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LSTA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LSTA and CRVS operate at a comparable scale, with $170,000 and $0 in trailing revenue.
| Metric | LSTALisata Therapeuti… | CRVSCorvus Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $170,000 | $0 |
| EBITDAEarnings before interest/tax | -$18M | -$48M |
| Net IncomeAfter-tax profit | -$17M | -$44M |
| Free Cash FlowCash after capex | -$16M | -$35M |
| Gross MarginGross profit ÷ Revenue | +91.2% | — |
| Operating MarginEBIT ÷ Revenue | -107.1% | — |
| Net MarginNet income ÷ Revenue | -97.6% | — |
| FCF MarginFCF ÷ Revenue | -94.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -90.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +40.0% | -15.4% |
LSTA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — LSTA and CRVS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | LSTALisata Therapeuti… | CRVSCorvus Pharmaceut… |
|---|---|---|
| Market CapShares × price | $29M | $1.2B |
| Enterprise ValueMkt cap + debt − cash | $13M | $1.2B |
| Trailing P/EPrice ÷ TTM EPS | -1.69x | -27.53x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 173.02x | — |
| Price / BookPrice ÷ Book value/share | 1.92x | 19.01x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — LSTA and CRVS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CRVS leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
CRVS delivers a -38.9% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-85 for LSTA. On the Piotroski fundamental quality scale (0–9), CRVS scores 3/9 vs LSTA's 1/9, reflecting mixed financial health.
| Metric | LSTALisata Therapeuti… | CRVSCorvus Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -85.5% | -38.9% |
| ROA (TTM)Return on assets | -70.8% | -35.7% |
| ROICReturn on invested capital | -2.3% | -78.1% |
| ROCEReturn on capital employed | -82.7% | -90.2% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | -$16M | -$4M |
| Cash & Equiv.Liquid assets | $16M | $5M |
| Total DebtShort + long-term debt | $0 | $937,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -18.29x |
CRVS leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CRVS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CRVS five years ago would be worth $50,137 today (with dividends reinvested), compared to $1,417 for LSTA. Over the past 12 months, CRVS leads with a +355.9% total return vs LSTA's +40.4%. The 3-year compound annual growth rate (CAGR) favors CRVS at 123.9% vs LSTA's -0.4% — a key indicator of consistent wealth creation.
| Metric | LSTALisata Therapeuti… | CRVSCorvus Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +64.8% | +99.3% |
| 1-Year ReturnPast 12 months | +40.4% | +355.9% |
| 3-Year ReturnCumulative with dividends | -1.2% | +1022.3% |
| 5-Year ReturnCumulative with dividends | -85.8% | +401.4% |
| 10-Year ReturnCumulative with dividends | -96.8% | +17.1% |
| CAGR (3Y)Annualised 3-year return | -0.4% | +123.9% |
CRVS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
LSTA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LSTA is the less volatile stock with a 1.17 beta — it tends to amplify market swings less than CRVS's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LSTA currently trades 63.7% from its 52-week high vs CRVS's 54.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LSTALisata Therapeuti… | CRVSCorvus Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.17x | 1.63x |
| 52-Week HighHighest price in past year | $5.07 | $26.95 |
| 52-Week LowLowest price in past year | $1.81 | $3.17 |
| % of 52W HighCurrent price vs 52-week peak | +63.7% | +54.1% |
| RSI (14)Momentum oscillator 0–100 | 35.1 | 49.2 |
| Avg Volume (50D)Average daily shares traded | 76K | 1.2M |
LSTA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | LSTALisata Therapeuti… | CRVSCorvus Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $33.17 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LSTA leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). CRVS leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallLisata Therapeutics, Inc. (LSTA)Leads 2 of 6 categories
Loading custom metrics...
LSTA vs CRVS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LSTA or CRVS a better buy right now?
Analysts rate Corvus Pharmaceuticals, Inc.
(CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LSTA or CRVS?
Over the past 5 years, Corvus Pharmaceuticals, Inc.
(CRVS) delivered a total return of +401. 4%, compared to -85. 8% for Lisata Therapeutics, Inc. (LSTA). Over 10 years, the gap is even starker: CRVS returned +17. 1% versus LSTA's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LSTA or CRVS?
By beta (market sensitivity over 5 years), Lisata Therapeutics, Inc.
(LSTA) is the lower-risk stock at 1. 17β versus Corvus Pharmaceuticals, Inc. 's 1. 63β — meaning CRVS is approximately 39% more volatile than LSTA relative to the S&P 500.
04Which is growing faster — LSTA or CRVS?
On earnings-per-share growth, the picture is similar: Corvus Pharmaceuticals, Inc.
grew EPS 48. 0% year-over-year, compared to 20. 4% for Lisata Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LSTA or CRVS?
Corvus Pharmaceuticals, Inc.
(CRVS) is the more profitable company, earning 0. 0% net margin versus -97. 6% for Lisata Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRVS leads at 0. 0% versus -107. 1% for LSTA. At the gross margin level — before operating expenses — LSTA leads at 14. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LSTA or CRVS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LSTA or CRVS better for a retirement portfolio?
For long-horizon retirement investors, Lisata Therapeutics, Inc.
(LSTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17)). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LSTA: -96. 8%, CRVS: +17. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LSTA and CRVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.